Cargando…

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer

PURPOSE: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical outcomes of pemetrexed-based chemotherapy in patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Jaemin, Kim, Se Hyun, Kim, Yu Jung, Lee, Juhyun, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog, Chung, Jin-Haeng, Jeon, Yoon Kyung, Lee, Jong Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823821/ https://www.ncbi.nlm.nih.gov/pubmed/29436187 http://dx.doi.org/10.3349/ymj.2018.59.2.202

Ejemplares similares

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
por: Choi, Ji Young, et al.
Publicado: (2019)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
por: Ock, Chan-Young, et al.
Publicado: (2019)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer
por: Yu, Zhengyi, et al.
Publicado: (2020)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer
por: Kim, Kyeong-Hyun, et al.
Publicado: (2013)

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma
por: Hong, Mi Jeong, et al.
Publicado: (2022)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Two Lung Masses with Different Responses to Pemetrexed
por: Park, Kwang Young, et al.
Publicado: (2010)

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
por: Park, Sojung, et al.
Publicado: (2016)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma
por: Lee, Yong Hoon, et al.
Publicado: (2023)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
por: Park, Ji Eun, et al.
Publicado: (2023)

Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Jung, Eun Hee, et al.
Publicado: (2021)

Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
por: Song, Zhengbo, et al.
Publicado: (2016)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2021)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
por: Heo, Ja Yoon, et al.
Publicado: (2021)

Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2021)

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
por: Lee, June-Koo, et al.
Publicado: (2015)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u6a0a2anaepoiqivto9e64ici9